Select an Industry Advertising Aerospace/Defense Agriculture Airlines/Aviation Art Auto Banking/Financial Services Beer, Wine & Spirits Biometrics Biotechnology Books Chemical Computer Hardware Computer Networks Computer Software Computer/Electronics Construction/Building Consumer Electronics Education Electronic Commerce Electronic Components Electronic Design Automation Electronic Gaming Electronics Performance Measurement Entertainment Environmental Services Fashion Film & Motion Picture Food/Beverages Gambling/Casinos Health Care/Hospitals High Tech Security Higher Education Homeland Security Household/Consumer/Cosmetics Infectious Disease Control Insurance Internet Technology Leisure/Tourism/Hotels Machinery Magazines Maritime/Shipbuilding Medical/Pharmaceuticals Mining/Metals Mobile Entertainment Multimedia/Online/Internet Music Mutual Funds Nanotechnology Office Products Oil/Energy OTC/SmallCap Paper/Forest Products/Containers Peripherals Public Safety Publishing/Information Services Radio Real Estate Restaurants Retail Semiconductors Sports Supermarkets Supplementary Medicine Telecommunications Television Textiles Tobacco Transportation/Trucking/Railroad Travel Utilities Workforce Management/Human Resources    

Alphabetical Listing: a b c d e f g h i j k l m n o p q r s t u v w x y z

BiPar Sciences Presents Initial Clinical Data of BSI-201, a Novel DNA Repair Inhibitor 34 days ago

BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer 39 days ago

BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 52 days ago

BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 59 days ago

BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies 83 days ago

BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer 87 days ago

BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer 143 days ago

BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 234 days ago

BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types 255 days ago

BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor 256 days ago

BiPar Announces Upcoming Data Presentations Demonstrating Progress on PARP Inhibitor Drug Pipeline for Cancer 258 days ago